# US 2011/0300579 A1 · Method of expressing proteins with disulfide bridges with enhanced yields and activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0300579 A1
- Document ID: US20110300579A1
- Status: Published application
- Kind: A1
- Application number: 13/127,970
- Filed: 2009-11-12
- Published: 2011-12-08
- Earliest claimed: 2008-11-13
- Assignees: University of Southern California
- Inventors: Radu O. Minea; Stephen D. Swenson; Francis S. Markland, JR.
- Web page: https://patentgrep.com/patent/US20110300579A1

## CPC

- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C07K 14/46: from vertebrates
- C12N 9/0036: {acting on NADH or NADPH (1.6)}
- C12Y 108/01007: Glutathione-disulfide reductase (1.8.1.7), i.e. glutathione reductase (NADPH)
- C12Y 108/01009: Thioredoxin-disulfide reductase (1.8.1.9), i.e. thioredoxin-reductase
- C07K 2319/35: containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Provided herein are methods for expressing proteins with disulfide bridges such as Vicrostatin (VCN), a chimeric variant of native snake venom disintegrin Contortrostatin (CN). The methods include what is believed to be a more efficient natural selection process that results in generating increased amounts of correctly-folded active conformers of proteins with disulfide bridges. In an aspect, this is achieved by growing Origami B cells in a more optimal redox environment during the induction of heterologous recombinant protein production.

## Claims

### Claim 1

A method of expressing non-procaryotic biologically active disulfide-rich protein in prokaryotic host cells said method comprising the steps:
a) obtaining a prokaryotic host cell transformed with an expression vector encoding a fusion protein under inducible control, said fusion protein comprising an N-terminal segment encoding thioredoxin and a C-terminal segment encoding said disulfide rich protein, wherein said host also carries stable mutations in thioredoxin reductase B (trxB) gene and/or the glutathione reductase (gor) gene, wherein said expression vector has an antibiotic resistance gene which makes it selectable on a first antibiotic, and wherein said trxB and gor mutations are selectable on at least one additional antibiotic to maintain the expression vector and trxB and gor mutations in said host cells during growth;
b) growing the host cells of step a) in the presence of the first and said at least one additional antibiotic to obtain a sufficient number of cells suitable to seed a reactor in which host cells will be grown and the fusion protein expression induced; and
c) seeding the reactor with the cells of step b) and growing the cells and inducing expression of the fusion protein, wherein said cells in the reactor are grown in the presence of the first antibiotic and in the absence of said at least one additional antibiotic.

### Claim 2 (depends on 1)

The method of claim 1 wherein the host cells express mutant products of both the trxB and gor genes.

### Claim 3 (depends on 1)

The method of claim 1 wherein said host cells are mutant in both trxB and gor genes.

### Claim 4 (depends on 3)

The method of claim 3 wherein the trxB and gor genes are selectable on different antibiotics.

### Claim 5 (depends on 1)

The method of claim 1 wherein the thioredoxin portion of the fusion protein comprises SEQ ID NO: 1.

### Claim 6 (depends on 1)

The method of claim 1 wherein the host is deficient in any one or more of ompT or Ion gene products.

### Claim 7 (depends on 1)

The method of claim 1 wherein a sequence encoding a cleavage site is located between the sequence encoding thioredoxin and the sequence encoding the disulfide rich protein.

### Claim 8 (depends on 1)

The method of claim 1 wherein the fusion protein further comprises a peptide sequence which is a ligand for a receptor.

### Claim 9 (depends on 1)

The method of claim 1 wherein the reactor comprises a fermentation vessel.

### Claim 10 (depends on 1)

The method of claim 1 wherein the prokaryotic host cell comprises a bacterial host cell.

### Claim 11 (depends on 1)

The method of claim 1 wherein said bacterial host cell comprises an Origami strain.

### Claim 12 (depends on 1)

The method of claim 1, further comprising a step following step c, wherein the cells are harvested and processed to obtain a purified preparation of said biologically active disulfide rich protein.

### Claim 13 (depends on 1)

The method of claim 1 wherein said biologically active disulfide rich protein is Vicrostatin (VCN), comprising the amino acid sequence of SEQ ID NO: 3.

### Claim 14 (depends on 13)

The method of claim 13 wherein said VCN is expressed as a monomer.

### Claim 15 (depends on 13)

The method of claim 13, wherein said biologically active VCN is at least 50% pure.

### Claim 16 (depends on 13)

The method of claim 13, wherein said biologically active VCN is at least 90% pure.

### Claim 17 (depends on 13)

The method of claim 13, wherein said biologically active VCN is at least 99% pure.

### Claim 18 (depends on 13)

The method of claim 13 wherein said biologically active VCN inhibits the migration of HUVEC, MDA-MB-435 or MDA-MB-231 cells.

### Claim 19 (depends on 13)

The method of claim 13 wherein said biologically active VCN increases the level of phosphorylation of FAK in MDA-MB-435 cells.

### Claim 20 (depends on 13)

The method of claim 13 wherein said biologically active VCN induces apoptosis in HUVECs in culture.

### Claim 21 (depends on 13)

The method of claim 13 wherein said biologically active VCN inhibits tube formation of HUVECs in culture.
